This controlled, sequential release strategy maximizes the synergistic anti‐leukemic efficacy of two agents with distinct mechanisms of action—simultaneously targeting Notch1‐mutated T‐ALL cells and compensating for each other's limitations. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.